A randomized phase II trial of gemcitabine, nab‐paclitaxel, cisplatin with or without a medically supervised ketogenic diet for patients with metastatic pancreatic cancer
Cancer · 2026
DOI: 10.1002/cncr.70343 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Cancer, 2026. Verfasst von Gayle S Jameson und 21 weiteren Autor:innen. Beteiligte Einrichtung: Oncology Division, HonorHealth Research Institute, Scottsdale, Arizona, USA. Hauptthemen laut MEDLINE: Diet, Ketogenic, Pancreatic Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Pancreatic Ductal. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ludwig Institute for Cancer Research, John E Sabga Foundation, Purple Pansies.
Abstract (Originalsprache)
Background
A randomized phase II screening trial of gemcitabine, nab‐paclitaxel, and cisplatin with a medically supervised ketogenic diet (MSKD) versus usual diet (non‐MSKD) was conducted in patients with treatment‐naive metastatic pancreatic ductal adenocarcinoma (PDAC).
Methods
Patients with untreated metastatic PDAC were randomized 1:1 to MSKD or non‐MSKD while receiving gemcitabine, nab‐paclitaxel, and cisplatin on days 1 and 8 of a 21‐day cycle. The MSKD was guided by a remote health care team and daily ketone (beta‐hydroxybutyrate) levels, with goal beta‐hydroxybutyrate of 0.5 to 3.0 mM. The primary endpoint was progression‐free survival (PFS) using a one‐sided alpha level of 0.20. Secondary endpoints included overall survival (OS), safety, and quality of life (QOL). Changes in microbiome were an exploratory endpoint.
Findings
Overall, there were 32 evaluable patients. In the MSKD arm, 15 of 16 patients achieved nutritional ketosis; the median proportion of days in ketosis was 39.4%. The median PFS was 8.5 months in MSKD patients and 6.2 months in non‐MSKD patients: hazard ratio, 0.53 (95% CI, 0.21–1.37); one‐sided p = .096. The median OS was 13.7 months with MSKD and 10.2 months in the non‐MSKD arm: hazard ratio, 0.58 (95% CI, 0.25–1.37); one‐sided p = .107). All MSKD‐related adverse events were grade 1‐2. There were no significant differences in grade ≥3 chemotherapy‐related adverse events between the arms. MSKD patients had no decline in QOL and had significant enrichment of beneficial taxa in the microbiome ( p < .05, log‐fold change ≥2).
Conclusions
The MSKD is feasible in patients with PDAC and, although not powered for definitive outcomes, shows trends in improved PFS and OS when combined with gemcitabine, nab‐paclitaxel, and cisplatin, without added toxicity or detriment to QOL. Larger studies are required to confirm these findings and establish the value of the MSKD in pancreatic cancer treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Oncology Division, HonorHealth Research Institute, Scottsdale, Arizona, USA.
- The University of Arizona Cancer Center, Tucson, Arizona, USA.
- School of Medicine and Advanced Medical Engineering, Arizona State University, Tempe, Arizona, USA.
- USC Norris Comprehensive Cancer Center, Medical Oncology, Los Angeles, California, USA.
- Research Department, Virta Health, Denver, Colorado, USA.
- Sarah Cannon Research Institute, Nashville, Tennessee, USA.
ORCID-Profile: Gayle S Jameson, Diana L Hanna, J Erin Wiedmeier-Nutor, Alison R Zoller, Keehoon Lee, Derek Cridebring
Förderung
- Ludwig Institute for Cancer Research
- John E Sabga Foundation
- Purple Pansies
- TGen's National Pancreatic Cancer Advisory Committee
Zitieren
APA
Jameson, G. S., Roe, D. J., Borazanci, E., Hanna, D. L., Roberts, C. G. P., Pelster, M. S., Frank, R. C., Alistar, A. T., Miller, A. M., Wiedmeier-Nutor, J. E., Algaze, S. D., Zoller, A. R., Hallberg, S. J., Wertheim, B. C., Lee, K., Cridebring, D., Rabinowitz, J. D., Gately, S., Keppler, J., …, & Rasco, D. W. (2026). A randomized phase II trial of gemcitabine, nab‐paclitaxel, cisplatin with or without a medically supervised ketogenic diet for patients with metastatic pancreatic cancer. Cancer. https://doi.org/10.1002/cncr.70343
Vancouver
Jameson GS, Roe DJ, Borazanci E, Hanna DL, Roberts CGP, Pelster MS, et al. A randomized phase II trial of gemcitabine, nab‐paclitaxel, cisplatin with or without a medically supervised ketogenic diet for patients with metastatic pancreatic cancer. Cancer. 2026. doi:10.1002/cncr.70343
BibTeX
@article{Jameson2026,
author = {Jameson, Gayle S and Roe, Denise J and Borazanci, Erkut and Hanna, Diana L and Roberts, Caroline G P and Pelster, Meredith S and Frank, Richard C and Alistar, Angela T and Miller, Alan M and Wiedmeier-Nutor, J Erin and Algaze, Sandra D and Zoller, Alison R and Hallberg, Sarah J and Wertheim, Betsy C and Lee, Keehoon and Cridebring, Derek and Rabinowitz, Joshua D and Gately, Stephen and Keppler, Jennifer and Sharma, Sunil and Von Hoff, Daniel D and Rasco, Drew W},
title = {A randomized phase II trial of gemcitabine, nab‐paclitaxel, cisplatin with or without a medically supervised ketogenic diet for patients with metastatic pancreatic cancer},
journal = {Cancer},
year = {2026},
doi = {10.1002/cncr.70343}
}
EUVIMED